|

Combined Brain Stimulation and Methylphenidate Treatment for Apathy in Dementia

RECRUITINGPhase 2Sponsored by Sunnybrook Health Sciences Centre
Actively Recruiting
PhasePhase 2
SponsorSunnybrook Health Sciences Centre
Started2026-01
Est. completion2027-10-01
Eligibility
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07279740

Summary

This study evaluates whether the combined treatment of methylphenidate and non-invasive brain stimulation, called intermittent theta burst stimulation, can effectively treat apathy in individuals with Alzheimer's disease or mixed AD/vascular dementia

Eligibility

Healthy volunteers accepted
Inclusion Criteria:

* Alzheimer's disease or mixed Alzheimer's disease and vascular disease
* MMSE score 10-28 inclusive
* Clinically significant apathy
* Stable dose of psychotropic medication
* Care partner must spend at least 10hrs/week with the participant

Exclusion Criteria:

* Major Depressive Episode
* Clinically significant agitation, delusions, hallucinations
* Currently talking a dopaminergic agent other than methylphenidate
* Failure to clear the TMS adult safety scale (e.g. unapproved pacemakers, metallic implants, history of epilepsy)
* Central nervous system abnormalities (other than Alzheimer's disease) deemed clinically significant by study physician or seizures
* Any condition that in the opinion of the study physician, makes it medically unsafe for the patient to enroll in the trial

Conditions6

Alzheimer DementiaAlzheimer Dementia (AD)Alzheimer DiseaseAlzheimer's DiseaseApathyApathy in Dementia

Browse More Trials

Alzheimer's Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.